View in EDS HTML Full Text PDF Full Text

What does the licensing of teplizumab mean for diabetes care?

Saved in:
Bibliographic Details
Title: What does the licensing of teplizumab mean for diabetes care?
Authors: Quinn LM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Swaby R; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK., Tatovic D; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK., Narendran P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.; Department of Diabetes, University Hospitals of Birmingham, Birmingham, UK., Besser REJ; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Department of Paediatrics, National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK., Dayan CM; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Diabetes Research Group, Cardiff University School of Medicine, Cardiff, UK.
Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Aug; Vol. 25 (8), pp. 2051-2057. Date of Electronic Publication: 2023 Apr 24.
Publication Type: Journal Article
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36999237
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: What does the licensing of teplizumab mean for diabetes care?
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Quinn+LM%22">Quinn LM</searchLink>; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Swaby+R%22">Swaby R</searchLink>; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Tatovic+D%22">Tatovic D</searchLink>; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Narendran+P%22">Narendran P</searchLink>; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.; Department of Diabetes, University Hospitals of Birmingham, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Besser+REJ%22">Besser REJ</searchLink>; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Department of Paediatrics, National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Dayan+CM%22">Dayan CM</searchLink>; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Diabetes Research Group, Cardiff University School of Medicine, Cardiff, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100883645%22">Diabetes, obesity & metabolism</searchLink> [Diabetes Obes Metab] 2023 Aug; Vol. 25 (8), pp. 2051-2057. <i>Date of Electronic Publication: </i>2023 Apr 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100883645 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1463-1326 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214628902%22">14628902 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Obes Metab <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36999237
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/dom.15071
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2051
    Titles:
      – TitleFull: What does the licensing of teplizumab mean for diabetes care?
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Quinn LM
      – PersonEntity:
          Name:
            NameFull: Swaby R
      – PersonEntity:
          Name:
            NameFull: Tatovic D
      – PersonEntity:
          Name:
            NameFull: Narendran P
      – PersonEntity:
          Name:
            NameFull: Besser REJ
      – PersonEntity:
          Name:
            NameFull: Dayan CM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2023 Aug
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1463-1326
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Diabetes, obesity & metabolism
              Type: main
ResultId 1